Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
GLP-1 is an incretin hormone which is discharged from the intestines after food intake. The hormone is known for its powerful insulinotropic and trophic effects on the beta cells in the pancreas and is currently used as an anti-diabetic agent in patients with type 2 diabetes (T2DM).
GLP-1 receptors are widely distributed including on the endothelial cells in both coronary and skeletal muscle circulation and on the myocardium. GLP-1-receptor studies on knock-out mice have shown that they exhibit a reduced myocardial contractility and reduced diastolic heart function. GLP-1 also shows beneficial cardiovascular effects in patients with acute myocardial infarctions and dogs with dilated cardiomyopathy in that the left ventricle function and endothelial dysfunction improves after GLP-1 treatment via insulin-independent mechanisms. Preclinical studies indicate that exogenous administrated GLP-1 in physiological concentrations can improve perfusion but this has never been tested in humans. It is also unknown whether GLP-1 can directly increase the glucose/metabolite uptake across both cardiac and skeletal muscle in an insulin independent manner. Unpublished studies do however indicate that the improvement in the cardiovascular system is largely dependent upon a high blood glucose level and only partially dependent upon the antiglycemic effects of GLP-1.
In the proposed studies the investigators wish to examine the physiological role of GLP-1 receptor stimulation both with regard to perfusion, metabolic improvement as well as cardiac inotropic. These studies will be conducted in both healthy and in T2DM patients.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes Mellitus |
Drug: Glucagon like peptide-1 Drug: Adenosine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | Endothelial and Metabolic Effects of GLP-1 in Coronary Circulation in Patients With Type 2 Diabetes Mellitus |
- Coronary blood flow [ Time Frame: 10 minutes after I.A. GLP-1 ] [ Designated as safety issue: No ]
- Coronary metabolite uptake [ Time Frame: 10 minutes after I.A. GLP-1 ] [ Designated as safety issue: No ]
| Enrollment: | 35 |
| Study Start Date: | June 2009 |
| Study Completion Date: | January 2012 |
| Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Type 2 Diabetes patients |
Drug: Glucagon like peptide-1
0,1 pmol/kg/min
Drug: Adenosine
20-40 microgram/minute
|
| Active Comparator: Healthy |
Drug: Glucagon like peptide-1
0,1 pmol/kg/min
Drug: Adenosine
20-40 microgram/minute
|
| Active Comparator: Artherosclerosis |
Drug: Glucagon like peptide-1
0,1 pmol/kg/min
Drug: Adenosine
20-40 microgram/minute
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Caucasians over 18
- Emitted for non-acute coronary arteriography (CAG) in Gentofte hospital
- BMI 23-35 kg/m2
- Normal hemoglobin
- Who gives informed consent
- Those with type 2 diabetes: HbA1c 6-10%
- Those without type 2 diabetes: Normal oral glucose tolerance test (OGTT) according to WHO criteria
Exclusion Criteria:
- Liver disease (ALAT > 2x normal)
- Diabetic nefropati (Creatinine > 130 µM or albuminuria)
- Treatment with medicine that cannot be paused 12 hours before intervention
- Pregnancy or breastfeeding
- Insulin- or glitazone treatment
- Healthy controls: close family history with diabetes
- Unstable angina pectoris
- Non-STEMI
- Atrial fibrillation
- Valvular disease
- LVEF < 50%
- Severe systemic disease
- Type 1 diabetes
Contacts and Locations| Denmark | |
| University Hospital Gentofte, Department of Cardiology | |
| Gentofte, Denmark, 2900 | |
| Study Chair: | Jan S Jensen, MD, DMSc | University hospital Gentofte, Department of Cardiology |
| Principal Investigator: | Jaya Rosenmeier, MD, Ph.D. | University hospital Gentofte, Department of Cardiology |
More Information
Publications:
| Responsible Party: | Jacob Christian Sivertsen, MD, University Hospital, Gentofte, Copenhagen |
| ClinicalTrials.gov Identifier: | NCT00923962 History of Changes |
| Other Study ID Numbers: | GLP-1 Coronary circulation 01 |
| Study First Received: | June 17, 2009 |
| Last Updated: | September 17, 2012 |
| Health Authority: | Denmark: The Regional Committee on Biomedical Research Ethics Denmark: National Board of Health |
Keywords provided by University Hospital, Gentofte, Copenhagen:
|
Basic science Type 2 Diabetes mellitus Glucagon like peptid-1 Coronary Bloodflow Metabolite uptake |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Adenosine Glucagon Glucagon-Like Peptide 1 Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anti-Arrhythmia Agents Cardiovascular Agents Vasodilator Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Gastrointestinal Agents Incretins |
ClinicalTrials.gov processed this record on May 16, 2013